Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CATX Perspective Therapeutics	$4.20 +1.7%	$3.25	$1.60 ▼ $16.55	$306.56M	1.18	1.09 million shs	924,507 shs
NNOX Nano-X Imaging	$5.14 +1.4%	$5.24	$3.75 ▼ $11.00	$296.98M	1.96	1.74 million shs	1.63 million shs
NVNO enVVeno Medical	$4.97 -5.3%	$3.99	$2.03 ▼ $5.92	$87.15M	0.93	116,152 shs	360,024 shs
SNWV Sanuwave Health	$39.24 +4.9%	$31.55	$5.17 ▼ $39.83	$336.26M	1.24	142,932 shs	111,101 shs

A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for July 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CATX Perspective Therapeutics	0.00%	+5.53%	+21.74%	+116.49%	-64.88%
NNOX Nano-X Imaging	0.00%	+1.58%	+1.78%	-1.15%	-39.67%
NVNO enVVeno Medical	0.00%	+18.90%	+20.34%	+102.86%	-16.47%
SNWV Sanuwave Health	0.00%	+12.82%	+18.91%	+30.89%	+3,923,999,900.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CATX Perspective Therapeutics	2.4135 of 5 stars	4.6	1.0	0.0	0.0	2.0	0.8	0.0
NNOX Nano-X Imaging	2.2413 of 5 stars	3.6	2.0	0.0	0.0	2.9	0.0	0.6
NVNO enVVeno Medical	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
SNWV Sanuwave Health	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CATX Perspective Therapeutics	3.18	Buy	$12.56	198.94% Upside
NNOX Nano-X Imaging	3.25	Buy	$9.50	84.82% Upside
NVNO enVVeno Medical	0.00	N/A	N/A	N/A
SNWV Sanuwave Health	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest NVNO, CATX, SNWV, and NNOX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/14/2025	NNOX Nano-X Imaging	LADENBURG THALM/SH SH Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
7/12/2025	CATX Perspective Therapeutics	Lifesci Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
6/23/2025	CATX Perspective Therapeutics	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$9.00 ➝ $12.00
6/23/2025	CATX Perspective Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$11.00
6/6/2025	NNOX Nano-X Imaging	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00
6/3/2025	CATX Perspective Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Outperform ➝ Moderate Buy	$15.00 ➝ $16.00
5/23/2025	NNOX Nano-X Imaging	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$15.00 ➝ $10.00
5/22/2025	NNOX Nano-X Imaging	Alliance Global Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
5/14/2025	CATX Perspective Therapeutics	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$10.00 ➝ $8.00
5/13/2025	CATX Perspective Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$11.00

(Data available from 7/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CATX Perspective Therapeutics	N/A	N/A	N/A	N/A	$2.67 per share	N/A
NNOX Nano-X Imaging	$11.55M	25.72	N/A	N/A	$3.27 per share	1.57
NVNO enVVeno Medical	N/A	N/A	N/A	N/A	$2.40 per share	N/A
SNWV Sanuwave Health	$32.63M	10.31	N/A	N/A	($1.49) per share	-26.34

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CATX Perspective Therapeutics	-$46.51M	N/A	0.00	N/A	N/A	-4,096.66%	-27.40%	-23.16%	8/13/2025 (Estimated)
NNOX Nano-X Imaging	-$53.52M	-$0.90	N/A	N/A	N/A	-472.19%	-30.92%	-27.73%	8/19/2025 (Estimated)
NVNO enVVeno Medical	-$21.82M	-$1.18	N/A	N/A	N/A	N/A	-51.32%	-48.23%	7/30/2025 (Estimated)
SNWV Sanuwave Health	-$31.37M	-$4.56	N/A	∞	N/A	-89.86%	N/A	-145.76%	N/A

Latest NVNO, CATX, SNWV, and NNOX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2025	N/A	CATX Perspective Therapeutics	-$0.30	N/A	N/A	N/A	$0.17 million	N/A
7/30/2025	N/A	NVNO enVVeno Medical	-$0.28	N/A	N/A	N/A	N/A	N/A
5/22/2025	Q1 2025	NNOX Nano-X Imaging	-$0.23	-$0.21	+$0.02	-$0.21	$3.98 million	$3.00 million
5/9/2025	Q1 2025	SNWV Sanuwave Health	N/A	-$0.66	N/A	-$0.66	N/A	$9.34 million
4/30/2025	Q1 2025	NVNO enVVeno Medical	N/A	-$0.22	N/A	-$0.22	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CATX Perspective Therapeutics	N/A	N/A	N/A	N/A	N/A
NNOX Nano-X Imaging	N/A	N/A	N/A	N/A	N/A
NVNO enVVeno Medical	N/A	N/A	N/A	N/A	N/A
SNWV Sanuwave Health	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CATX Perspective Therapeutics	N/A	9.60	9.60
NNOX Nano-X Imaging	N/A	5.30	5.16
NVNO enVVeno Medical	N/A	23.77	23.77
SNWV Sanuwave Health	N/A	0.40	0.28

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CATX Perspective Therapeutics	54.66%
NNOX Nano-X Imaging	21.49%
NVNO enVVeno Medical	34.71%
SNWV Sanuwave Health	42.53%

Insider Ownership

Company	Insider Ownership
CATX Perspective Therapeutics	3.72%
NNOX Nano-X Imaging	7.74%
NVNO enVVeno Medical	16.00%
SNWV Sanuwave Health	14.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CATX Perspective Therapeutics	70	74.23 million	65.21 million	Optionable
NNOX Nano-X Imaging	190	57.78 million	53.31 million	Optionable
NVNO enVVeno Medical	30	17.54 million	14.73 million	Optionable
SNWV Sanuwave Health	40	8.57 million	7.29 million	N/A

NVNO, CATX, SNWV, and NNOX Headlines

Recent News About These Companies

Sanuwave: High Growth Wound Care Tech Primed For A Breakout

June 11, 2025 | seekingalpha.com

Sanuwave Health Appoints Industry Veteran Dustin Libby as Executive Vice President of Commercial Operations

June 3, 2025 | globenewswire.com

SANUWAVE Health, Inc. (SNWV): A Bull Case Theory

May 29, 2025 | insidermonkey.com

Sanuwave Health Appoints Greg Bazar to Board of Directors

May 28, 2025 | globenewswire.com

Sanuwave Health Selected for Inclusion in Russell 2000Â® Index

May 28, 2025 | globenewswire.com

Insider Selling: SANUWAVE Health, Inc. (NASDAQ:SNWV) Insider Sells 3,639 Shares of Stock

May 17, 2025 | insidertrades.com

SANUWAVE Health, Inc. (SNWV) Q1 2025 Earnings Call Transcript

May 9, 2025 | seekingalpha.com

Sanuwave Announces Q1 FY2025 Financial Results

May 9, 2025 | globenewswire.com

Sanuwave Will Host a Conference Call on May 9, 2025 at 8:30 AM (ET) to Present Q1 2025 Financial Results

May 5, 2025 | globenewswire.com

SANUWAVE Health Announces Preliminary Revenue Results for the First Quarter 2025 (Ended March 31, 2025)

April 8, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

NVNO, CATX, SNWV, and NNOX Company Descriptions

Perspective Therapeutics NYSE:CATX

$4.20 +0.07 (+1.69%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$4.22 +0.02 (+0.48%)

As of 07/18/2025 07:51 PM Eastern

Perspective Therapeutics, Inc., together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma. Perspective Therapeutics, Inc. has a clinical trial collaboration agreement with Bristol Myers Squibb to evaluate the safety and tolerability of [212Pb] VMT01 in combination with nivolumab in patients with histologically confirmed melanoma and positive MC1R imaging scans. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 1998 and is headquartered in Seattle, Washington.

Nano-X Imaging NASDAQ:NNOX

$5.14 +0.07 (+1.38%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$5.12 -0.01 (-0.29%)

As of 07/18/2025 07:58 PM Eastern

Nano-X Imaging Ltd. develops a commercial-grade tomographic imaging device with a digital X-ray source. The company provides teleradiology services and develops artificial intelligence applications to be used in real-world medical imaging applications. Its X-ray source is based on a digital micro-electro-mechanical systems semiconductor cathode. The company's solutions include Nanox Multi Source System comprising Nanox.ARC, a medical tomographic imaging system incorporating its digital X-ray source, and Nanox. CLOUD, a platform which employs a matching engine to match medical images to radiologists that provides image repository, connectivity to diagnostic assistive AI systems, billing, and reporting. It also offers Nanox.MARKETPLACE, which connects imaging facilities with radiologists and enables radiologists to provide, as well as customers to obtain remote interpretations of imaging data; artificial intelligence (AI)-based software imaging solutions to hospitals, health maintenance organizations, integrated delivery networks, pharmaceutical companies, and insurers that are designed to identify or predict undiagnosed or underdiagnosed medical conditions through the mining of data included in images of existing computed tomography scans for osteoporosis and cardiovascular disease; Teleradiology Services, which provide imaging interpretation services for radiology practices, hospitals, medical clinics, diagnostic imaging centers, urgent care facilities; and multi-specialty physician groups, contracts, and radiology readings. The company is headquartered in Petach Tikva, Israel.

enVVeno Medical NASDAQ:NVNO

$4.97 -0.28 (-5.33%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$5.04 +0.08 (+1.51%)

As of 07/18/2025 07:46 PM Eastern

enVVeno Medical Corporation (Nasdaq: NVNO) is an medical device company focused on the development of innovative bioprosthetic (tissue-based) devices to improve the standard of care in the treatment of venous disease. The company's lead product, the VenoValve®️, is a first-in-class, surgical implant being developed for the treatment of severe deep venous Chronic Venous Insufficiency (CVI). Deep venous CVI occurs when valves inside of the deep veins of the leg become damaged, resulting in insufficient blood being returned to the heart. The malfunctioning vein valves cause blood to flow backwards (reflux) and pool in the lower leg, increasing the pressure within the veins of the leg (venous hypertension). In the most severe cases, CVI can lead to venous ulcers (open skin sores) that become chronic and difficult to heal. The VenoValve is implanted in the femoral vein and works as a replacement venous valve, designed to reduce reflux and venous hypertension, and to restore proper directional blood flow back to the heart. With severe deep venous CVI impacting an estimated 2.4 million people in the U.S., who have no effective treatment options, the VenoValve has received Breakthrough Device Designation from the U.S. Food and Drug Administration, and is currently being evaluated in the SAVVE U.S. clinical trial.

Sanuwave Health NASDAQ:SNWV

$39.24 +1.82 (+4.86%)

As of 07/18/2025 04:00 PM Eastern

SANUWAVE Health, Inc., a shock wave technology company, researches, develops, and commercializes noninvasive, high-energy, and acoustic shock waves for regenerative medicine and other applications in the United States and internationally. Its shockwaves are used to produce a biological response resulting in the body healing itself through the repair and regeneration of tissue, and musculoskeletal and vascular structures. The company's lead regenerative product is the dermaPACE device for treating diabetic foot ulcers. Its portfolio of healthcare products and product candidates activate biologic signaling and angiogenic responses, including new vascularization and microcirculatory improvement, which helps to restore the body's normal healing processes and regeneration. The company also focuses on applying its Pulsed Acoustic Cellular Expression technology in wound healing, orthopedic, plastic/cosmetic, and cardiac conditions. In addition, it offers UltraMIST, non-contact and non-thermal ultrasound therapy device used to treat diabetic foot ulcers, pressure ulcers, venous leg ulcers, deep tissue pressure injuries, and surgical wounds; and orthoPACE system to treat tendinopathies and acute and nonunion fractures. The company was founded in 2005 and is headquartered in Suwanee, Georgia.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time